A protocol published in PLOS ONE lays out how researchers plan to map evidence on remimazolam, a sedative, for adults aged 65 and older undergoing gastrointestinal endoscopy. The paper, authored by Shuang Tao, X. Li, Z. Zhou and H. Zhang, describes a scoping review that has not yet reported findings. Its purpose is to show what research exists, how it was conducted and where important gaps remain.

The authors frame the question around an aging endoscopy population and concerns about sedation-related complications. Their protocol says older patients face greater risks of cardiorespiratory events, delayed recovery and postoperative neurocognitive disturbances. It describes remimazolam as an ultra-short-acting benzodiazepine metabolized by tissue esterases, with clearance largely independent of liver and kidney function. That pharmacological rationale makes it a candidate of interest, but it does not establish how well it works for older endoscopy patients.

The protocol notes that earlier meta-analyses have compared remimazolam with propofol in general adult populations and reported broadly favorable results. Whether those findings apply to older adults is uncertain, the authors say. Studies may define “elderly” using different age cutoffs, ranging from 60 to 80, and may vary in whether they report frailty, cognitive status or other patient characteristics. They also use different drug regimens, comparators and definitions of outcomes such as sedation success, low blood pressure, breathing problems and delayed recovery. Such differences can make results difficult to compare.

To map that landscape, the planned review will include clinical studies of people aged 65 or older having procedures such as gastroscopy, colonoscopy and therapeutic endoscopy. It will chart how studies define older age; which remimazolam doses and administration methods they use; what other medications are given; how sedation is monitored; and which outcomes are measured. The reviewers also plan to record study designs, comparators and care settings.

The search is planned across international and Chinese databases, trial registries and additional sources, covering reports from 2015 through the final search date. The protocol limits eligibility to English- and Chinese-language reports, which the authors say reflects the substantial Chinese-language literature in this field. Two reviewers will independently screen records and extract information. The plan also includes descriptive checks of methodological quality for randomized and nonrandomized studies.

The review is designed to organize evidence, not calculate whether remimazolam is safer or more effective than another sedative. The authors say they will not conduct a meta-analysis, and that the expected variation among studies will limit quantitative synthesis. They also acknowledge that restricting the review to English and Chinese may miss relevant reports, particularly from Japan and Korea, and that a rapidly growing research area means the review will represent a snapshot.

The authors expect the resulting evidence map to help identify gaps and inform the design of future trials with more consistent definitions and outcomes that matter to patients. The protocol itself offers no treatment conclusions or recommendations. It records a plan for a review; the studies it finds, and what they can establish, remain to be seen.